These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 68613)

  • 21. Study on tuberactinomycin-N. I. In vitro Antibacterial activity of TUM-N on Tubercle bacilli isolated from patients.
    Shimizu T
    Jpn J Antibiot; 1974 Aug; 27(4):463-70. PubMed ID: 4140247
    [No Abstract]   [Full Text] [Related]  

  • 22. [Critical concentrations for resistances of tubercle bacilli to tuberactinomycin-N, viomycin, capreomycin, and lividomycin in patients treated with these agents (cross-resistance-relationships among resistances to aminoglucoside-antibiotics found during chemotherapy for tuberculosis) (author's transl)].
    Tsukamura M; Mizuno S; Murata H; Oshima T
    Kekkaku; 1975 May; 50(4-5):123-30. PubMed ID: 49449
    [No Abstract]   [Full Text] [Related]  

  • 23. [In vitro experiment showing that chemotherapy of tuberculosis by aminoglycoside antibiotics may influence successive chemotherapy with rifampicin].
    Tsukamura M
    Kekkaku; 1991 Jan; 66(1):13-8. PubMed ID: 1901613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drug resistance of tubercle bacilli -- from the clinical point of view (author's transl)].
    Fukuhara Y
    Kekkaku; 1976 Dec; 51(12):477-87. PubMed ID: 65494
    [No Abstract]   [Full Text] [Related]  

  • 25. Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of the conjugation system.
    Taniguchi H; Chang B; Abe C; Nikaido Y; Mizuguchi Y; Yoshida SI
    J Bacteriol; 1997 Aug; 179(15):4795-801. PubMed ID: 9244267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The antimycobacterial activity of capreomycin.
    Lucchesi M
    Antibiot Chemother; 1970; 16():27-31. PubMed ID: 4108891
    [No Abstract]   [Full Text] [Related]  

  • 27. Amikacin in the treatment of pulmonary tuberculosis.
    Allen BW; Mitchison DA; Chan YC; Yew WW; Allan WG; Girling DJ
    Tubercle; 1983 Jun; 64(2):111-8. PubMed ID: 6193623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Development of resistance of Mycobacterium tuberculosis to cycloserine, ethionamide, kanamycin, florimycin in experiments in vitro].
    Mkrtchian SV
    Antibiotiki; 1968 Oct; 13(10):907-10. PubMed ID: 4303355
    [No Abstract]   [Full Text] [Related]  

  • 29. Resistance system of Mycobacterium bovis B.C.B. to aminoglycoside- and peptide-antibiotics. Comparison of resistant phenotypes between Mycobacterium tuberculosis and Mycobacterium bovis.
    Tsukamura M
    Microbiol Immunol; 1980; 24(1):11-9. PubMed ID: 6153747
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug-resistance test for kanamycin and cross resistance problem in Mycobacterium tuberculosis with special reference to kanamycin, streptomycin, and viomycin.
    TSUKAMURA M
    J Antibiot (Tokyo); 1959 Jul; 12():189-91. PubMed ID: 13855139
    [No Abstract]   [Full Text] [Related]  

  • 31. [In vitro susceptibility testing of nontuberculous mycobacteria to streptomycin, kanamycin and enviomycin].
    Tsukamura M
    Kekkaku; 1989 Sep; 64(9):557-62. PubMed ID: 2554046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The susceptibility of mycobacteria to rifamide and rifampicin.
    Clark J; Wallace A
    Tubercle; 1967 Jun; 48(2):144-8. PubMed ID: 4293697
    [No Abstract]   [Full Text] [Related]  

  • 33. [In vitro antituberculous activity of lividomycin].
    Kobayashi F; Nagoya T; Eda J; Yoshimura Y
    Jpn J Antibiot; 1972 Dec; 25(6):360-6. PubMed ID: 4125073
    [No Abstract]   [Full Text] [Related]  

  • 34. The genetic basis of cross-resistance between streptomycin, viomycin and kanamycin of tubercle bacilli and atypical mycobacteria.
    Bönicke J; Bönicke R
    Bull Int Union Tuberc; 1970 Jun; 43():229-34. PubMed ID: 4316621
    [No Abstract]   [Full Text] [Related]  

  • 35. [Drug resistance in Mycobacteria (author's transl)].
    Yamada T; Masuda K
    Kekkaku; 1976 Oct; 51(10):399-406. PubMed ID: 64637
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.
    Engström A; Perskvist N; Werngren J; Hoffner SE; Juréen P
    J Antimicrob Chemother; 2011 Jun; 66(6):1247-54. PubMed ID: 21427106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and biochemical studies on drug-resistant mutants in Mycobacterium smegmatis.
    Mizuguchi Y; Suga K; Masuda K; Yamada T
    Jpn J Microbiol; 1974 Nov; 18(6):457-62. PubMed ID: 4141739
    [No Abstract]   [Full Text] [Related]  

  • 38. A COMPARATIVE STUDY OF THE SUSCEPTIBILITY TO STREPTOMYCIN, CYCLOSERINE, VIOMYCIN, AND KANAMYCIN OF TUBERCLE BACILLI FROM 100 PATIENTS NEVER TREATED WITH CYCLOSERINE, VIOMYCIN, OR KANAMYCIN.
    HOK TT; SENG TK
    Am Rev Respir Dis; 1964 Dec; 90():961-2. PubMed ID: 14233803
    [No Abstract]   [Full Text] [Related]  

  • 39. STUDIES ON CROSS-RESISTANCE BETWEEN CAPREOMYCIN AND CERTAIN OTHER ANTI-MYCOBACTERIAL AGENTS.
    KOSEKI Y; OKAMOTO S
    Jpn J Med Sci Biol; 1963 Feb; 16():31-8. PubMed ID: 14044251
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic determinants of aminoglycoside resistance in strains of Mycobacterium tuberculosis.
    Alberghina M; Nicoletti G; Torrisi A
    Chemotherapy; 1973; 19(3):148-60. PubMed ID: 4358199
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.